Pharmexa: Interim report for the first 6 months of the financial year 2003
21. August 2003 08:17 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Aug. 21, 2003 (PRIMEZONE) -- Summary: The Pharmexa (Other:PMXAY) Group had turnover of kDKK 8,138 in the first 6 months of 2003 and realised a net loss of kDKK 69,337. Research and...
Pharmexa Submits Application to Start Clinical Phase I Trial in Breast Cancer
08. April 2003 11:39 ET
|
Pharmexa A/S
HORSHOLM, Denmark, April 8, 2003 (PRIMEZONE) -- Pharmexa (Other OTC:PMXAY) has submitted an application to start a clinical phase I trial with the company's HER-2 Protein AutoVac(TM) product to the...
Pharmexa Submits Application to Start Clinical Phase II Trial in Breast Cancer
08. April 2003 10:36 ET
|
Pharmexa A/S
HORSHOLM, Denmark, April 8, 2003 (PRIMEZONE) -- Pharmexa (Other OTC:PMXAY) has submitted an application to start a clinical phase II trial with the company's HER-2 DNA AutoVac(TM)product to the...
Pharmexa A/S Annual Report 2002
05. März 2003 10:31 ET
|
Pharmexa A/S
HORSHOLM, Denmark, March 5, 2003 (PRIMEZONE) -- The Board of Directors of Pharmexa A/S (Other OTC:PMXAY) has approved the audited financial statements for the financial year 2002.
The Pharmexa...
Pharmexa Focuses and Adjusts the Organization
29. Januar 2003 05:26 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, Jan. 29, 2003 (PRIMEZONE) -- As first announced on September 10, 2002, Pharmexa (Other OTC:PMXAY) is increasingly focusing its resources on the most advanced products, the HER-2...
Positive Results of Clinical Phase I/II Trial on Pharmexa's HER-2 DNA Autovac Breast Cancer Product
12. Dezember 2002 03:48 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, Dec. 12, 2002 (PRIMEZONE) - Pharmexa A/S (Other OTC:PMXAY) (Copenhagen:PHARMX) discloses very promising results from a phase I/II clinical trial on the HER-2 DNA AutoVac(TM)...
H. Lundbeck and Pharmexa Achieve Important Milestone in Research Collaboration
10. Dezember 2002 10:48 ET
|
Pharmexa A/S
HORSHOLM, Denmark, Dec. 10, 2002 (PRIMEZONE) -- Pharmexa (Other OTC:PMXAY) today announced important progress in a research collaboration with H. Lundbeck established in April 2000. The focus of the...
Pharmexa: Interim Report for the First 9 Months of the Financial Year 2002
21. November 2002 09:07 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, Nov. 21, 2002 (PRIMEZONE) -- Summary: Pharmexa (Other OTC:PMXAY) made important progress in Q3. Based on positive results from the clinical phase I/II trial soon to be completed,...
ING Initiates Coverage on Pharmexa with a Buy Recommendation
02. Oktober 2002 08:32 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, Oct. 2, 2002 (PRIMEZONE) -- Pharmexa A/S (Copenhagen:PHARMX) today announced that ING Financial Markets has initiated coverage of its stock. The research report, published today,...
Pharmexa Buys the AutoVac TNF-Alpha Pharmaccine
09. September 2002 06:36 ET
|
Pharmexa A/S
HOERSHOLM, Denmark, Sept. 9, 2002 (PRIMEZONE) -- Pharmexa has bought back the AutoVac(TM) TNF-alpha pharmaccine from Business Development Finance (Vaekstfonden).
In 1997, Pharmexa signed a license...